Liver Toxicity in HIV - Infected Patients Receiving Antiretroviral Therapy That Includes HIV - I Protease Inhibitors.

The present paper describes possible connections between antiretroviral therapies (ARTs) - Protease Inhibitor Drugs, used to treat human immunodeficiency virus (HIV) infection and adverse drug reactions (ADRs) encountered predominantly in the liver. Similarly, hepatitis B and /or C virus confection has been associated with a greater risk of Drug - Induced liver Injury, compared with those with no Hepatitis. The study includes prescriptions of 50 HIV seropositive patients (aged between 10 and 50 years) who reported for treatment at the outpatient ward of Santosh Medical College Hospital & Research Centre, Ghaziabad. Since After initiation to therapy, serum AST and ALT levels increased significantly to 32% and 18% and Serum HBs Ag and HCV levels increased significantly to 36% and 20%.The study affirms the potential risk of hepatotoxicity for HIV seropositive patients on an Antiretroviral Protease Inhibitor drugs and calls for continuous monitoring of ARV administration so as to prevent fatal effects of hepatotoxicity.